Stockreport

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

Neurogene Inc.  (NGNE) 
PDF Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollmentNew preclinical data at ESGCT Congress highlight NGN-401 best-in-class p [Read more]